Insider Selling: Regulus Therapeutics Director Sells 1,850 Shares of Stock (RGLS)
Regulus Therapeutics (NASDAQ:RGLS) Director Isis Pharmaceuticals Inc unloaded 1,850 shares of Regulus Therapeutics stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $6.80, for a total value of $12,580.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Several analysts have recently commented on the stock. Analysts at FBR Capital Markets raised their price target on shares of Regulus Therapeutics from $14.00 to $15.00 in a research note on Thursday. They now have an “outperform” rating on the stock. Analysts at Brinson Patrick initiated coverage on shares of Regulus Therapeutics in a research note on Tuesday, May 13th. They set an “outperform” rating on the stock. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $16.20.
Shares of Regulus Therapeutics (NASDAQ:RGLS) traded up 1.34% on Friday, hitting $6.81. 43,818 shares of the company’s stock traded hands. Regulus Therapeutics has a one year low of $5.40 and a one year high of $11.88. The stock’s 50-day moving average is $7. and its 200-day moving average is $7.98. The company’s market cap is $295.3 million.
Regulus Therapeutics (NASDAQ:RGLS) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.10. Analysts expect that Regulus Therapeutics will post $-0.89 EPS for the current fiscal year.
Regulus Therapeutics Inc, is a biopharmaceutical company focused on discovering and developing microRNAs to treat a range of diseases.
Receive News & Ratings for Regulus Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.